Co-Diagnostics, Inc. 8-K

What Happened Co-Diagnostics, Inc. (CODX) announced in an 8-K filed January 13, 2026 that Nasdaq’s Listing Qualifications Staff determined to delist the company’s common stock from The Nasdaq Capital Market for failure to meet the minimum $1.00 bid price required by Nasdaq Listing Rule 5550(a)(2). The company said it will timely request a hearing before the Nasdaq Hearings Panel, but trading of CODX on Nasdaq will be suspended at the open on January 14, 2026 and the shares are expected to trade on the OTC Market’s Pink Limited Information tier under the ticker “CODX.”

Key Details

• Nasdaq delisting notice was disclosed in the 8-K filed January 13, 2026; suspension effective at market open on January 14, 2026.
• Company previously notified on January 10, 2025 of non-compliance; first 180-day cure period expired July 9, 2025 and a second 180-day period expired January 5, 2026.
• Co-Diagnostics completed a 1-for-30 reverse stock split effective January 2, 2026; the bid price has closed at or above $1.00 per share since January 2, 2026.
• If the stock records a closing bid of at least $1.00 for a minimum 10 consecutive business-day period ending January 15, 2026, the company will seek a compliance determination from Nasdaq and may cancel the hearing request — but there is no assurance this will prevent the suspension.

Why It Matters A Nasdaq suspension and move to the OTC Pink tier can materially affect retail investors: trading liquidity and visibility typically decline on OTC markets, and spreads may widen. The company’s reverse split and recent closes at or above $1.00 may allow it to regain compliance if it sustains the $1.00 threshold for the required 10 consecutive business days, but the filing makes clear there is no guarantee of regaining Nasdaq listing or reversing the suspension timing. Investors should note the effective suspension date (Jan 14, 2026) and the conditions for potential reinstatement, and consider the potential impacts on liquidity and trading execution.